| Application no. and date | 16702654.1 (espacenet) (Federated) (European Patent Register), 20160122 | | Patent/reg. no. and date | DK/EP 3250575, 20191120 | | Publication date | 20171206 | | Priority no. and date | US 201562109733 P, 20150130 | | EP pub. no. and date |
EP 3250575 20171206 | | Effective date | | | Applicant/owner | Eli Lilly and Company, Lilly Corporate Center
Indianapolis, IN 46285, US | | Applicant ref. no. | P81904919DK00E | | Inventor | COATES, David Andrew, c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288, US,
WOLFANGEL, Craig Daniel, c/o Eli Lilly and Company
P. O. Box 6288
Indianapolis, Indiana 46206-6288, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/542 (2006.01) , A61P 25/28 (2006.01) , C07D 513/04 (2006.01) | | Title | TOSYLATSALT AF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUORPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUOR-PHENYL]-5-METHOXY-PYRAZIN-2-CARBOXAMID | | Int. application no. | US2016014423 | | Int. publication no. | WO2016122968 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
